99
Participants
Start Date
September 1, 2022
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Sutetinib Maleate Capsule
Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
RECRUITING
University of Maryland Medical Center, Baltimore
RECRUITING
FirstHealth Cancer Center, Pinehurst
RECRUITING
University Cancer & Blood Center, Athens
RECRUITING
Baptist Health, Louisville
RECRUITING
The University of Texas- MD Anderson Cancer Center, Houston
RECRUITING
OPN Healthcare, Inc., Glendale
ACTIVE_NOT_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
ACTIVE_NOT_RECRUITING
Beijing Cancer Hospital, Beijing
ACTIVE_NOT_RECRUITING
Peking Union Medical College Hospital, Beijing
ACTIVE_NOT_RECRUITING
Beijing Chest Hospital, Beijing
ACTIVE_NOT_RECRUITING
Jilin Cancer Hospital, Changchun
ACTIVE_NOT_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
ACTIVE_NOT_RECRUITING
Shanghai Chest Hospital, Shanghai
ACTIVE_NOT_RECRUITING
Shanghai Pulmonary Hospital, Shanghai
ACTIVE_NOT_RECRUITING
Jiangsu Province Hospital, Nanjing
ACTIVE_NOT_RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
ACTIVE_NOT_RECRUITING
Linyi Cancer Hospital, Linyi
ACTIVE_NOT_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
ACTIVE_NOT_RECRUITING
The Affiliated Cancer Hospital of Chongqin University, Chongqing
ACTIVE_NOT_RECRUITING
Hunan Cancer Hospital, Changsha
ACTIVE_NOT_RECRUITING
Wuhan Union Hospital of China, Wuhan
ACTIVE_NOT_RECRUITING
Henan Cancer Hospital, Zhengzhou
ACTIVE_NOT_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
ACTIVE_NOT_RECRUITING
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
ACTIVE_NOT_RECRUITING
Sichuan Cancer Hospital, Chengdu
ACTIVE_NOT_RECRUITING
The First Affiliated Hospital of China Medical University, Shengyang
Teligene US
INDUSTRY